Menu Search
Equities

Exagen Inc

XGN:NMQ

Exagen Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)4.10
  • Today's Change0.18 / 4.59%
  • Shares traded120.45k
  • 1 Year change+162.82%
  • Beta1.4617
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Exagen Inc grew revenues 15.33% from 45.56m to 52.55m while net income improved from a loss of 47.39m to a smaller loss of 23.69m.
Gross margin58.80%
Net profit margin-30.36%
Operating margin-27.62%
Return on assets-32.39%
Return on equity-83.86%
Return on investment-39.53%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Exagen Inc fell by 25.90m. Cash Flow from Investing was negative at 804.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 14.46m for operations while cash used for financing totalled 10.63m.
Cash flow per share-0.837
Price/Cash flow per share--
Book value per share0.7345
Tangible book value per share0.7345
More ▼

Balance sheet in USDView more

Exagen Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.51% of the market capitalization can be attributed to its 36.49m and debt could be paid in full if management chose.
Current ratio4.05
Quick ratio--
Total debt/total equity1.60
Total debt/total capital0.6148
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.